ME02202B - Jedinjenja pirolopirimidina kao inhibitori cdk4/6 - Google Patents
Jedinjenja pirolopirimidina kao inhibitori cdk4/6Info
- Publication number
- ME02202B ME02202B MEP-2015-157A MEP15715A ME02202B ME 02202 B ME02202 B ME 02202B ME P15715 A MEP15715 A ME P15715A ME 02202 B ME02202 B ME 02202B
- Authority
- ME
- Montenegro
- Prior art keywords
- pirolopyrimidine
- cdk4
- inhibitors
- compounds
- pirolopyrimidine compounds
- Prior art date
Links
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30624810P | 2010-02-19 | 2010-02-19 | |
| US201161429372P | 2011-01-03 | 2011-01-03 | |
| US201161429997P | 2011-01-05 | 2011-01-05 | |
| EP11707115.9A EP2536730B1 (en) | 2010-02-19 | 2011-02-17 | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 |
| PCT/EP2011/052353 WO2011101409A1 (en) | 2010-02-19 | 2011-02-17 | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02202B true ME02202B (me) | 2016-02-20 |
Family
ID=44201966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-157A ME02202B (me) | 2010-02-19 | 2011-02-17 | Jedinjenja pirolopirimidina kao inhibitori cdk4/6 |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8957074B2 (me) |
| EP (1) | EP2536730B1 (me) |
| JP (1) | JP5788415B2 (me) |
| KR (1) | KR101812357B1 (me) |
| CN (1) | CN102918043B (me) |
| AR (1) | AR080198A1 (me) |
| AU (1) | AU2011217286B2 (me) |
| BR (1) | BR112012020922B1 (me) |
| CA (1) | CA2790637C (me) |
| CL (1) | CL2012002270A1 (me) |
| DK (1) | DK2536730T3 (me) |
| DO (1) | DOP2012000225A (me) |
| EA (1) | EA022355B1 (me) |
| EC (1) | ECSP12012111A (me) |
| ES (1) | ES2548532T3 (me) |
| GE (1) | GEP20146146B (me) |
| HK (1) | HK1176616A1 (me) |
| HN (1) | HN2012001744A (me) |
| HR (1) | HRP20151071T1 (me) |
| IL (1) | IL221520A (me) |
| MA (1) | MA34066B1 (me) |
| ME (1) | ME02202B (me) |
| MX (1) | MX2012009613A (me) |
| NI (1) | NI201200135A (me) |
| NZ (1) | NZ601754A (me) |
| PE (1) | PE20121815A1 (me) |
| PH (1) | PH12012501649A1 (me) |
| PL (1) | PL2536730T3 (me) |
| PT (1) | PT2536730E (me) |
| RS (1) | RS54263B1 (me) |
| SG (1) | SG183218A1 (me) |
| SI (1) | SI2536730T1 (me) |
| SM (1) | SMT201500265B (me) |
| TN (1) | TN2012000413A1 (me) |
| TW (1) | TWI503322B (me) |
| UA (1) | UA108369C2 (me) |
| UY (1) | UY33227A (me) |
| WO (1) | WO2011101409A1 (me) |
| ZA (1) | ZA201206079B (me) |
Families Citing this family (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122020016659B8 (pt) | 2005-05-10 | 2021-07-27 | Incyte Holdings Corp | moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| LT2824100T (lt) | 2008-07-08 | 2018-05-10 | Incyte Holdings Corporation | 1,2,5-oksadiazolai, kaip indolamino 2,3-dioksigenazės inhibitoriai |
| DK2331547T3 (da) | 2008-08-22 | 2014-11-03 | Novartis Ag | Pyrrolopyrimidinforbindelser som CDK-inhibitorer |
| ES2663536T3 (es) | 2008-09-26 | 2018-04-13 | Oncomed Pharmaceuticals, Inc. | Agentes que se unen a receptores frizzled y usos de los mismos |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| ES2689177T3 (es) * | 2010-04-13 | 2018-11-08 | Novartis Ag | Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| US8501768B2 (en) * | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
| ES2676180T3 (es) | 2011-07-01 | 2018-07-17 | Novartis Ag | Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer |
| US20150132301A1 (en) * | 2011-12-09 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Combination Therapy for Treatment of Cancer |
| EP2831080B1 (en) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
| SMT202000673T1 (it) | 2012-06-13 | 2021-01-05 | Incyte Holdings Corp | Composti triciclici sostituiti come inibitori di fgfr |
| LT2872491T (lt) | 2012-07-11 | 2021-08-25 | Blueprint Medicines Corporation | Fibroblasto augimo faktoriaus receptoriaus inhibitoriai |
| WO2014022830A2 (en) | 2012-08-03 | 2014-02-06 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
| EP3514158B1 (en) | 2013-01-29 | 2022-10-12 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| EP2968290B1 (en) | 2013-03-15 | 2019-09-25 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| US20140271460A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly Active Anti-Neoplastic and Anti-Proliferative Agents |
| SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| ES2900829T3 (es) * | 2013-08-14 | 2022-03-18 | Novartis Ag | Terapia combinada para el tratamiento del cáncer |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US20150297607A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy |
| JP2017516855A (ja) * | 2014-05-28 | 2017-06-22 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | 特定のタンパク質キナーゼ阻害剤 |
| CN105294737B (zh) * | 2014-07-26 | 2019-02-12 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| EP3191468B1 (en) * | 2014-09-11 | 2018-12-12 | Janssen Pharmaceutica NV | Substituted 2-azabicycles and their use as orexin receptor modulators |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| CN105111201B (zh) * | 2014-10-16 | 2017-01-11 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| UA121669C2 (uk) | 2015-02-20 | 2020-07-10 | Інсайт Корпорейшн | Біциклічні гетероцикли як інгібітори fgfr |
| US10449211B2 (en) | 2015-03-10 | 2019-10-22 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling |
| ES2806206T3 (es) * | 2015-03-11 | 2021-02-16 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivado de 2-hidrógeno pirazol sustituido que sirve como fármaco anticanceroso |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| LT3370768T (lt) | 2015-11-03 | 2022-05-25 | Janssen Biotech, Inc. | Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| AU2016365400C1 (en) * | 2015-12-02 | 2022-11-10 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
| BR112018012138A2 (pt) | 2015-12-17 | 2018-12-04 | Novartis Ag | moléculas de anticorpo para pd-1 e usos das mesmas |
| US11077110B2 (en) | 2016-03-18 | 2021-08-03 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| AU2017262155B2 (en) * | 2016-05-07 | 2021-03-11 | Fochon Pharmaceuticals, Ltd. | Certain protein kinase inhibitors |
| CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US11299495B2 (en) * | 2016-08-01 | 2022-04-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CA3031534C (en) | 2016-08-01 | 2023-10-17 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| MX2019001308A (es) | 2016-08-01 | 2019-05-30 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos. |
| US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
| EP3528812B1 (en) | 2016-10-20 | 2020-12-30 | Pfizer Inc | Palbociclib for treating pah |
| WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
| WO2018089518A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| RU2747311C2 (ru) | 2016-12-16 | 2021-05-04 | СиСТОУН ФАРМАСЬЮТИКАЛС (СУЧЖОУ) КО., ЛТД. | Ингибитор CDK4/6 |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN108794452B (zh) | 2017-05-05 | 2021-05-28 | 上海时莱生物技术有限公司 | 具有激酶抑制活性的化合物、其制备方法和用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| RU2019142591A (ru) | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
| RU2020124138A (ru) | 2017-12-22 | 2022-01-24 | Хиберселл, Инк. | Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы |
| BR112020013915A2 (pt) | 2018-01-08 | 2020-12-01 | G1 Therapeutics, Inc. | regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano |
| BR112020015710A2 (pt) | 2018-01-31 | 2020-12-08 | Aptinyx Inc. | Moduladores de espiro-lactamas de receptores nmda e usos dos mesmos |
| AU2019220746A1 (en) * | 2018-02-15 | 2020-08-27 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| KR20200139153A (ko) | 2018-02-27 | 2020-12-11 | 인사이트 코포레이션 | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 |
| KR20200132902A (ko) * | 2018-03-13 | 2020-11-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Egfr 활성화 돌연변이를 갖는 암의 치료 방법 |
| FI3788047T3 (fi) | 2018-05-04 | 2024-11-02 | Incyte Corp | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
| EP3840756A4 (en) | 2018-08-24 | 2022-04-27 | G1 Therapeutics, Inc. | IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| EP3863638B1 (en) * | 2018-10-12 | 2024-06-26 | Board of Regents of the University of Nebraska | Phosphodiesterase inhibitors |
| CN111100128B (zh) * | 2018-10-26 | 2022-09-06 | 广安凯特制药有限公司 | 一种瑞博西尼中间产品的合成方法及其中间体化合物 |
| US20230065740A1 (en) * | 2018-12-28 | 2023-03-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| EA202192260A1 (ru) | 2019-02-15 | 2021-12-17 | Инсайт Корпорейшн | Биомаркеры циклин-зависимой киназы 2 и их применение |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN112094272A (zh) | 2019-06-18 | 2020-12-18 | 北京睿熙生物科技有限公司 | Cdk激酶抑制剂 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220044527A (ko) | 2019-08-01 | 2022-04-08 | 인사이트 코포레이션 | Ido 억제제의 투여 요법 |
| EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157681A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20230017165A (ko) | 2020-03-06 | 2023-02-03 | 인사이트 코포레이션 | Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법 |
| BR112022020841A2 (pt) | 2020-04-16 | 2023-05-02 | Incyte Corp | Inibidores de kras tricíclicos fundidos |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| WO2021236650A1 (en) | 2020-05-19 | 2021-11-25 | G1 Therapeutics, Inc. | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| CN112375081B (zh) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022155941A1 (en) | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
| WO2022206888A1 (en) | 2021-03-31 | 2022-10-06 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| KR20240032915A (ko) | 2021-07-07 | 2024-03-12 | 인사이트 코포레이션 | Kras의 저해제로서의 삼환식 화합물 |
| JP2024529347A (ja) | 2021-07-14 | 2024-08-06 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としての三環式化合物 |
| WO2023009438A1 (en) | 2021-07-26 | 2023-02-02 | Celcuity Inc. | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
| JP2024534187A (ja) | 2021-08-31 | 2024-09-18 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としてのナフチリジン化合物 |
| CN117043163A (zh) * | 2021-09-08 | 2023-11-10 | 希格生科（深圳）有限公司 | 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途 |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| US12030884B2 (en) | 2021-10-01 | 2024-07-09 | Incyte Corporation | Pyrazoloquinoline KRAS inhibitors |
| CR20240197A (es) | 2021-10-14 | 2024-08-07 | Incyte Corp | Compuestos de quinolina como inhibidores de kras |
| EP4436578A1 (en) | 2021-11-22 | 2024-10-02 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a kras inhibitor |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| AU2022418585A1 (en) | 2021-12-22 | 2024-07-11 | Incyte Corporation | Salts and solid forms of an fgfr inhibitor and processes of preparing thereof |
| WO2023116884A1 (en) | 2021-12-24 | 2023-06-29 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
| WO2023168686A1 (en) | 2022-03-11 | 2023-09-14 | Qilu Regor Therapeutics Inc. | Substituted cyclopentanes as cdk2 inhibitors |
| AR128717A1 (es) | 2022-03-07 | 2024-06-05 | Incyte Corp | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 |
| WO2023213271A1 (en) * | 2022-05-05 | 2023-11-09 | Beigene , Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2023250430A1 (en) | 2022-06-22 | 2023-12-28 | Incyte Corporation | Bicyclic amine cdk12 inhibitors |
| WO2024015731A1 (en) | 2022-07-11 | 2024-01-18 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
| WO2024026290A1 (en) * | 2022-07-25 | 2024-02-01 | Cayman Chemical Company Incorporated | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS |
| WO2024026484A2 (en) * | 2022-07-29 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| WO2024220645A1 (en) | 2023-04-18 | 2024-10-24 | Incyte Corporation | 2-azabicyclo[2.2.1]heptane kras inhibitors |
| US20240390340A1 (en) | 2023-04-18 | 2024-11-28 | Incyte Corporation | Pyrrolidine kras inhibitors |
| WO2024254245A1 (en) | 2023-06-09 | 2024-12-12 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| MXPA04008592A (es) | 2002-03-07 | 2004-12-06 | Hoffmann La Roche | Inhibidores de piridina biciclica y pirimidina p38 cinasa. |
| DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| RU2351590C2 (ru) | 2003-02-10 | 2009-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения диариламина |
| EA200600372A1 (ru) | 2003-09-05 | 2006-08-25 | Ньюроджин Корпорейшн | Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1) |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| WO2005047289A1 (en) | 2003-11-17 | 2005-05-26 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| US7319102B1 (en) | 2003-12-09 | 2008-01-15 | The Procter & Gamble Company | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors |
| PE20051089A1 (es) * | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
| WO2005080393A1 (en) | 2004-02-14 | 2005-09-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CN1926140A (zh) | 2004-03-05 | 2007-03-07 | 大正制药株式会社 | 吡咯并嘧啶衍生物 |
| EP1735307B1 (en) | 2004-04-07 | 2012-08-29 | Novartis AG | Inhibitors of iap |
| WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| US20080167309A1 (en) | 2004-07-22 | 2008-07-10 | Astex Therapeutics, Ltd. | Pharmaceutical Compounds |
| WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| ES2508766T3 (es) | 2004-10-29 | 2014-10-16 | Janssen R&D Ireland | Derivados de pirimidina bicíclicos que inhiben el VIH |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| AU2006205851A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| JP2006241089A (ja) | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
| WO2006137769A1 (en) | 2005-06-20 | 2006-12-28 | Astrazeneca Ab | Process for the preparation of 3,7-dihydroxy-1,5-diazacyclooctanes |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| WO2007030438A2 (en) | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| GB0520164D0 (en) | 2005-10-04 | 2005-11-09 | Novartis Ag | Organic compounds |
| PT1947098E (pt) | 2005-10-06 | 2012-01-12 | Nippon Soda Co | Compostos de amina cíclicos e agente para controlo de pragas |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| WO2007075783A2 (en) | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
| BRPI0709007A2 (pt) | 2006-03-09 | 2011-06-21 | Pharmacopeia Inc | inibidores de 8-heteroarilpurina mnk2 para tratamento de distúrbios metabólicos |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| EP2209789B1 (en) | 2007-11-20 | 2011-11-16 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| AU2008343932B2 (en) * | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| KR20130066703A (ko) | 2008-02-06 | 2013-06-20 | 노파르티스 아게 | 피롤로［２,３ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도 |
| WO2009115084A2 (de) | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Neue pyrrolopyrimidin-derivate und deren verwendungen |
| DK2331547T3 (da) | 2008-08-22 | 2014-11-03 | Novartis Ag | Pyrrolopyrimidinforbindelser som CDK-inhibitorer |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| ES2689177T3 (es) | 2010-04-13 | 2018-11-08 | Novartis Ag | Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
-
2011
- 2011-02-15 UY UY33227A patent/UY33227A/es not_active Application Discontinuation
- 2011-02-17 PH PH1/2012/501649A patent/PH12012501649A1/en unknown
- 2011-02-17 BR BR112012020922-1A patent/BR112012020922B1/pt active IP Right Grant
- 2011-02-17 PE PE2012001259A patent/PE20121815A1/es not_active Application Discontinuation
- 2011-02-17 PT PT117071159T patent/PT2536730E/pt unknown
- 2011-02-17 JP JP2012553318A patent/JP5788415B2/ja active Active
- 2011-02-17 KR KR1020127024329A patent/KR101812357B1/ko active IP Right Grant
- 2011-02-17 AR ARP110100478 patent/AR080198A1/es unknown
- 2011-02-17 MX MX2012009613A patent/MX2012009613A/es active IP Right Grant
- 2011-02-17 ME MEP-2015-157A patent/ME02202B/me unknown
- 2011-02-17 PL PL11707115T patent/PL2536730T3/pl unknown
- 2011-02-17 CA CA2790637A patent/CA2790637C/en active Active
- 2011-02-17 EA EA201201161A patent/EA022355B1/ru not_active IP Right Cessation
- 2011-02-17 UA UAA201209879A patent/UA108369C2/uk unknown
- 2011-02-17 SI SI201130591T patent/SI2536730T1/sl unknown
- 2011-02-17 SG SG2012058566A patent/SG183218A1/en unknown
- 2011-02-17 RS RS20150623A patent/RS54263B1/en unknown
- 2011-02-17 CN CN201180021222.6A patent/CN102918043B/zh active Active
- 2011-02-17 GE GEAP201112834A patent/GEP20146146B/en unknown
- 2011-02-17 EP EP11707115.9A patent/EP2536730B1/en active Active
- 2011-02-17 WO PCT/EP2011/052353 patent/WO2011101409A1/en active Application Filing
- 2011-02-17 US US13/579,359 patent/US8957074B2/en active Active
- 2011-02-17 ES ES11707115.9T patent/ES2548532T3/es active Active
- 2011-02-17 MA MA35209A patent/MA34066B1/fr unknown
- 2011-02-17 AU AU2011217286A patent/AU2011217286B2/en active Active
- 2011-02-17 NZ NZ60175411A patent/NZ601754A/en not_active IP Right Cessation
- 2011-02-17 DK DK11707115.9T patent/DK2536730T3/en active
- 2011-02-18 TW TW100105536A patent/TWI503322B/zh not_active IP Right Cessation
-
2012
- 2012-08-14 ZA ZA2012/06079A patent/ZA201206079B/en unknown
- 2012-08-15 TN TNP2012000413A patent/TN2012000413A1/en unknown
- 2012-08-16 IL IL221520A patent/IL221520A/en not_active IP Right Cessation
- 2012-08-17 HN HN2012001744A patent/HN2012001744A/es unknown
- 2012-08-17 NI NI201200135A patent/NI201200135A/es unknown
- 2012-08-17 CL CL2012002270A patent/CL2012002270A1/es unknown
- 2012-08-17 DO DO2012000225A patent/DOP2012000225A/es unknown
- 2012-08-20 EC ECSP12012111 patent/ECSP12012111A/es unknown
-
2013
- 2013-03-27 HK HK13103855.3A patent/HK1176616A1/xx not_active IP Right Cessation
-
2014
- 2014-12-12 US US14/568,410 patent/US9309252B2/en active Active
-
2015
- 2015-10-07 HR HRP20151071TT patent/HRP20151071T1/hr unknown
- 2015-10-28 SM SM201500265T patent/SMT201500265B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02202B (me) | Jedinjenja pirolopirimidina kao inhibitori cdk4/6 | |
| SMT201600311B (it) | Inibitori di cdk | |
| SMT201500271B (it) | Inibitori di neprilisina | |
| HK1212914A1 (zh) | 用於抑制聚合酶的吡咯並嘧啶衍生物 | |
| SMT201600008B (it) | Composti di piridazinone | |
| BR112013009935C8 (pt) | compostos | |
| BR112013003753A2 (pt) | compostos | |
| ME02186B (me) | Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori | |
| CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| SMT201500291B (it) | Nuovi agenti antimalarici | |
| CO6930358A2 (es) | Compuestos inhibidores de metaloenzimas | |
| DK2371923T3 (da) | Aflejringshæmmer | |
| ME02900B (me) | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze | |
| DK2648516T3 (da) | Substituerede pyridinon-pyridinylforbindelser | |
| HUE043536T2 (hu) | PDK1 inhibitorként alkalmazható heterociklusos vegyületek | |
| BR112013014986A2 (pt) | compostos inseticidas | |
| SMT201600328B (it) | Nuovi composti come inibitori di diacilglicerolo aciltransferasi | |
| DK2540728T3 (da) | Heterocyklisk forbindelse | |
| HRP20151310T1 (xx) | Spojevi piridazinona i njihova uporaba kao inhibitori daao | |
| CO6801726A2 (es) | Compuestos | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| BR112013025761A2 (pt) | inibidores de hsp90 | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| DK2649070T3 (da) | Triazolpyridinforbindelser | |
| IL225895A0 (en) | Anti-diabetic compounds |